Seer (SEER) to Release Quarterly Earnings on Wednesday

Seer (NASDAQ:SEER) is scheduled to be releasing its earnings data after the market closes on Wednesday, May 8th. Analysts expect Seer to post earnings of ($0.31) per share for the quarter. Seer has set its FY 2024 guidance at EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Seer (NASDAQ:SEER) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.07. The firm had revenue of $4.44 million for the quarter, compared to analyst estimates of $4.24 million. Seer had a negative net margin of 517.84% and a negative return on equity of 20.87%. On average, analysts expect Seer to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Seer Stock Performance

Shares of Seer stock opened at $2.24 on Tuesday. Seer has a 1-year low of $1.46 and a 1-year high of $5.65. The business has a 50-day moving average of $1.87 and a 200-day moving average of $1.77.

Insider Buying and Selling at Seer

In other Seer news, CEO Omid Farokhzad sold 52,857 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $2.03, for a total transaction of $107,299.71. Following the sale, the chief executive officer now owns 1,436,285 shares in the company, valued at $2,915,658.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 15.02% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley restated an “equal weight” rating and set a $7.00 price objective on shares of Seer in a report on Tuesday, March 5th.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.